55 related articles for article (PubMed ID: 38609918)
1. Continuous immunotherapy beyond progression in clinical practice for small cell lung cancer.
Yamamoto K; Ninomaru T; Okada H; Hirano K; Shimada T; Hata A
Thorac Cancer; 2024 May; 15(15):1271-1275. PubMed ID: 38623812
[TBL] [Abstract][Full Text] [Related]
2. A case of pulmonary tuberculosis that developed during nivolumab and ipilimumab treatment for pulmonary adenocarcinoma that recurred two months after completion of anti-tuberculous treatment.
Hirano S; Takahashi H; Nakamura S; Matsuda K; Ishikawa R; Tamura K; Shikano K; Fujita T; Amano H; Nakamura M
Chin Clin Oncol; 2024 May; ():. PubMed ID: 38859608
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-17A Inhibitors in Patients with Psoriasis and Tuberculosis Infection: A 2-Year Prospective Study on Safety Without Preventive Treatment.
He CX; Wu C; Zhang L; Jin HZ
Dermatol Ther (Heidelb); 2024 Apr; 14(4):893-906. PubMed ID: 38483777
[TBL] [Abstract][Full Text] [Related]
4. Vitiligo-like Lesions as a Predictor of Response to Immunotherapy in Non-Small Cell Lung Cancer: Comprehensive Review and Case Series from a University Center.
Coelho JQ; Romão R; Sousa MJ; Azevedo SX; Fidalgo P; Araújo A
Curr Oncol; 2024 Feb; 31(2):1113-1128. PubMed ID: 38392077
[TBL] [Abstract][Full Text] [Related]
5. Deciphering the Correlation between the Emergence of Lung Carcinoma Associated with Tuberculosis-related Inflammation.
Chauhan P; Pandey P; Ramniwas S; Khan F; Maqsood R
Endocr Metab Immune Disord Drug Targets; 2024 May; ():. PubMed ID: 38831573
[TBL] [Abstract][Full Text] [Related]
6. Tuberculosis infection following immune checkpoint inhibitor treatment for advanced cancer: a case report and literature review.
Lin C; Xu G; Gao S; Feng T; Li S
Front Immunol; 2023; 14():1162190. PubMed ID: 37304292
[TBL] [Abstract][Full Text] [Related]
7. Impact of immune checkpoint inhibitors (ICIs) therapy on interferon-γ release assay (IGRA) and diagnostic value in non-small cell lung cancer (NSCLC) patients.
Xu Y; Zhang Q; Chen Z; Yang S; Chen H; Xiao X; Jiang H
BMC Pulm Med; 2024 Apr; 24(1):174. PubMed ID: 38609918
[TBL] [Abstract][Full Text] [Related]
8. T-cell response to phytohemagglutinin in the interferon-γ release assay as a potential biomarker for the response to immune checkpoint inhibitors in patients with non-small cell lung cancer.
Kamimaki C; Kobayashi N; Hirata M; Somekawa K; Fukuda N; Kubo S; Katakura S; Teranishi S; Watanabe K; Horita N; Hara Y; Yamamoto M; Kudo M; Piao H; Kaneko T
Thorac Cancer; 2021 Jun; 12(11):1726-1734. PubMed ID: 33943031
[TBL] [Abstract][Full Text] [Related]
9. Serial interferon-gamma release assay in lung cancer patients receiving immune checkpoint inhibitors: a prospective cohort study.
Fujita K; Elkington P; Redelman-Sidi G; Kanai O; Yamamoto Y; Imakita T; Okamura M; Nakatani K; Mio T
Cancer Immunol Immunother; 2022 Nov; 71(11):2757-2764. PubMed ID: 35429244
[TBL] [Abstract][Full Text] [Related]
10. Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy.
Chen HW; Kuo YW; Chen CY; Chang CH; Wang SM; Chien YC; Lu WC; Chen JP; Chang CY; Wei YF; Chang SC; Shu CC; Wang JY; Liao WY; Wang HC; Yu CJ
Oncologist; 2024 Apr; 29(4):e498-e506. PubMed ID: 38227604
[TBL] [Abstract][Full Text] [Related]
11. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Chen H; Han KD; He ZJ; Huang YS
Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149
[TBL] [Abstract][Full Text] [Related]
12. East Asian patients who received immunotherapy-based therapy associated with improved survival benefit in advanced non-small cell lung cancer: An updated meta-analysis.
Yao Y; Li B; Xu Y; Yang L; Zou B; Wang L
Cancer Med; 2024 Feb; 13(4):e7080. PubMed ID: 38457254
[TBL] [Abstract][Full Text] [Related]
13. The Bidirectional Relationship between Pulmonary Tuberculosis and Lung Cancer.
Preda M; Tănase BC; Zob DL; Gheorghe AS; Lungulescu CV; Dumitrescu EA; Stănculeanu DL; Manolescu LSC; Popescu O; Ibraim E; Mahler B
Int J Environ Res Public Health; 2023 Jan; 20(2):. PubMed ID: 36674038
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
